Eli Lilly and Company ($LLY) Stock Forecast: Down 10.2% Today

What is Eli Lilly and Company?

Eli Lilly (LLY) is a pharmaceutical company recognized for its innovative drugs and treatments. The stock has demonstrated recent positive performance trends in both short-term and long-term perspectives.

Why is Eli Lilly and Company going down?

LLY stock is down 10.2% on May 1, 2025 16:44

• In spite of the strong upward momentum witnessed over the previous month and year, Eli Lilly (LLY) encountered a downward movement in its stock price today.
• This shift can be linked to the company falling short of Q1 earnings expectations, with a -5.11% surprise in earnings and a 0.86% miss in revenue.
• Moreover, the reduction in projected 2025 profit due to IPR&D-related expenses may have influenced investor sentiment, contributing to today's decline in the stock price.
• Investors are advised to keep a close watch on upcoming earnings releases and updates regarding the company's profitability forecast to assess the potential recovery of the stock from the current bearish trend.

LLY Price Chart

LLY Technical Analysis

LLY News

Mounjaro Maker Eli Lilly Clocks 45% Jump In Q1 Revenue, Cuts 2025 Profit Outlook But Not Due To Tariffs - Eli Lilly ( NYSE:LLY )

Eli Lilly Q1 revenue rose 45% to $12.73 billion; Mounjaro sales surged 113% to $3.84 billion, Zepbound hit $2.31 billion. 2025 EPS forecast cut to $20.78-$22.28 from $22.50-$24.00 due to $1.57 billion in IPR&D charges.

https://www.benzinga.com/general/biotech/25/05/45136276/mounjaro-maker-eli-lilly-clocks-45-jump-in-q1-revenue-cuts-2025-profit-outlook-but-not-due-to-tar

Eli Lilly ( LLY ) Q1 Earnings Lag Estimates

Lilly (LLY) delivered earnings and revenue surprises of -5.11% and 0.86%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2459802/eli-lilly-lly-q1-earnings-lag-estimates

Eli Lilly Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Eli Lilly ( NYSE:LLY )

Eli Lilly and Company LLY will release earnings results for the first quarter, before the opening bell on Thursday, May 1. Analysts expect the Indianapolis, Indiana-based company to report quarterly earnings at $3.46 per share, up from $2.58 per share in the year-ago period.

https://www.benzinga.com/25/05/45126308/eli-lilly-gears-up-for-q1-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts

Eli Lilly Stock Has The Technicals: Will Q1 Earnings Deliver Fundamentals? - Eli Lilly ( NYSE:LLY )

Eli Lilly stock trades above all major moving averages, indicating a strongly bullish technical trend. Analysts see 3% upside, but momentum indicators suggest the rally could have more room to run. Feel unsure about the market's next move?

https://www.benzinga.com/general/biotech/25/04/45112166/eli-lilly-stock-has-the-technicals-will-q1-earnings-deliver-fundamentals

Price Over Earnings Overview: Eli Lilly - Eli Lilly ( NYSE:LLY )

In the current session, the stock is trading at $893.76, after a 0.97% increase. Over the past month, Eli Lilly Inc. LLY stock increased by 9.23%, and in the past year, by 18.24%.

https://www.benzinga.com/insights/news/25/04/45107634/price-over-earnings-overview-eli-lilly

Trending Today

NVIDIA Corporation ($NVDA) Stock Forecast: Up 5.5% Today

Movement ($MOVE) Crypto Forecast: Down 16.5% Today

Datadog Inc. ($DDOG) Stock Forecast: Up 5.1% Today

Ventas Inc. ($VTR) Stock Forecast: Down 5.3% Today

MANTRA ($OM) Crypto Forecast: Down 5.1% Today

Natural Gas ($GAS) Commodity Forecast: Up 5.1% Today

Sui ($SUI) Crypto Forecast: Up 6.5% Today

Kohl's Corporation ($KSS) Stock Forecast: Up 10.1% Today

Riot Platforms, Inc. ($RIOT) Stock Forecast: Up 7.2% Today

POL (Polygon) ($POL) Crypto Forecast: Up 5.1% Today

Eli Lilly and Company Price History

17.03.2025 - LLY Stock was up 15.4%

• Eli Lilly's stock soared after its oral GLP-1 drug, Orforglipron, successfully met Phase 3 goals in a diabetes trial, showing promising results in reducing A1C levels and weight in patients.
• Analysts are optimistic about the global potential of Orforglipron, with sales forecasts exceeding consensus estimates, leading to increased investor confidence in Eli Lilly's future prospects.
• The launch of Eli Lilly's weight-loss drug, Mounjaro, in India has triggered a craze in the market, showcasing the company's ability to innovate and capture consumer interest in new products.
• The positive news surrounding Eli Lilly's drug developments contrasts with Pfizer's decision to halt obesity pill development due to safety concerns, further highlighting the importance of successful clinical trials in the pharmaceutical industry.

17.03.2025 - LLY Stock was up 11.4%

• Eli Lilly's stock saw a significant rise following positive results from its oral GLP-1 drug, Orforglipron, in a Phase 3 diabetes trial, demonstrating effectiveness in reducing A1C levels and weight for those with type 2 diabetes.
• The introduction of Eli Lilly's weight-loss medication, Mounjaro, into the Indian market sparked enthusiasm among investors, generating increased interest and positive outlook for the company.
• Speculations suggest that Pfizer's decision to halt an obesity drug development program on safety grounds may have contributed to further enhancing investor trust in Eli Lilly's innovative and secure drug portfolio, propelling its stock price upwards.
• In conclusion, Eli Lilly's recent accomplishments in drug trials and strategic product releases have solidified its position as a key player in the pharmaceutical sector. This has attracted investors and fueled the positive momentum in its stock performance.

20.11.2024 - LLY Stock was up 5.2%

• Eli Lilly's stock rose notably following the endorsement from the European Medicines Agency (EMA) panel for expanded use of Omvoh in treating Crohn's Disease, underscoring the company's dedication to developing effective treatments.
• Despite another company's weight loss drug not meeting expectations, Eli Lilly's positive updates overshadowed any potential negativity in the pharmaceutical sector.
• The bearish options trends in Eli Lilly's stock may have been counterbalanced by the favorable endorsement from the CHMP, boosting investor confidence and fueling the upward trend.
• With speculation around the next trillion-dollar company, Eli Lilly's progress in healthcare solutions positions it well for potential future growth and market valuation.

04.03.2025 - LLY Stock was down 6.8%

• Eli Lilly stock saw a notable decline despite a recent license agreement with Sangamo Therapeutics expected to bring in substantial revenue.
• Uncertainty over proposed tariffs on pharmaceutical imports by the current administration has had a negative impact on Eli Lilly, Pfizer (PFE), and Merck (MRK) stocks.
• Although there was smart money interest and support from financial giants, Eli Lilly's stock faced a significant decline, likely influenced by broader market conditions and tariff-related concerns outweighing positive developments.

14.00.2025 - LLY Stock was down 5.1%

• Despite the overall market decline, Eli Lilly's stock price increased by +1.07%.
• The acquisition of Scorpion Therapeutics' early-stage cancer program for $2.5 billion could have positively influenced investor sentiment towards Eli Lilly.
• The anticipation of weight loss resolutions in the new year may have contributed to the optimistic outlook for Eli Lilly's stock.
• Investors holding onto Eli Lilly stock despite a recent 14% fall in the past 3 months indicates confidence in the company's future growth prospects.

09.03.2025 - LLY Stock was down 6.9%

• The partnership between Sangamo Therapeutics and Eli Lilly might have caused investors to shift their focus towards Sangamo, leading to a sell-off in LLY.
• Investors may see Sangamo's potential for significant earnings through the license agreement as a more attractive opportunity compared to LLY's current market position.
• The competition between LLY and NVO in the weight-loss drug sector could also be influencing investor sentiment, with some choosing to reallocate their investments from LLY to NVO.

07.02.2025 - LLY Stock was down 5.2%

• The partnership between Teladoc Health and Eli Lilly's LillyDirect to expand access to Zepbound for weight loss possibly sparked concerns among investors about the competitive landscape in the weight management sector, influencing a bearish sentiment towards Eli Lilly.
• The bullish options activity on Eli Lilly might reflect conflicting sentiments among investors, with some anticipating positive outcomes while others exercise caution, contributing to the stock's downward trend.
• Novo Nordisk's efforts to enhance Wegovy access through reduced pricing and home delivery could have exerted pressure on Eli Lilly's stock as investors reassess the competitive pricing and accessibility of weight management treatments in the market.
• Despite Eli Lilly's historical superior performance over the last two decades, recent developments and competitive pressures in the weight management sector may have cast a shadow on its long-term success, triggering a bearish market movement today.

10.03.2025 - LLY Stock was down 5.4%

• Wealthy investors have taken a pessimistic position on Eli Lilly, as evidenced by the latest options trends, potentially impacting the stock's downturn.
• The announcement of a 90-day pause on tariffs by President Trump benefited pharmaceutical stocks, including Eli Lilly, but the initial effects of the anticipated import tariff had already negatively influenced the stock price.
• The collaboration update with Sangamo Therapeutics could have initially boosted investor confidence. However, various market conditions seemed to overshadow this positive development, contributing to Eli Lilly's stock decline.
• In summary, the combination of bearish options trends, tariff uncertainties, and general market instability likely played a role in the downward trend of Eli Lilly's stock today.

06.01.2025 - LLY Stock was up 3.1%

• Q4 earnings report for Eli Lilly exceeded expectations, showing a 45% YoY revenue increase driven by strong demand for Mounjaro and Zepbound.
• The company's 2025 sales forecast of $58B-$61B, with a 32% growth midpoint, fueled investor optimism and contributed to the bullish momentum in the stock.
• Analysts are bullish on LLY, with price targets averaging $1066, indicating a 27% upside potential, supported by the anticipated success of new medicines and expanded market launches.
• The positive sentiment surrounding Eli Lilly's earnings and future prospects likely led to the strong bullish movement in the stock today.

14.00.2025 - LLY Stock was down 6.3%

• Eli Lilly cut its Q4 revenue guidance, expecting around $5.5 billion in sales from weight loss/diabetes drugs, leading to a bearish sentiment among investors.
• The acquisition of Scorpion Therapeutics' early-stage cancer program for $2.5 billion might have raised concerns about the company's future expenses and profitability.
• The comparison with Novo Nordisk as the best weight loss stock for 2025 could have shifted investor focus and triggered profit-taking in Eli Lilly shares.
• Despite the recent decline in stock price, analysts suggest holding onto Eli Lilly due to its robust growth prospects, indicating a potential rebound in the future.

01.04.2025 - LLY Stock was down 6.1%

• Despite a positive earnings forecast for the first quarter, Eli Lilly (LLY) saw a significant bearish movement.
• Some market influencers in LLY options trading displayed a bearish sentiment, potentially impacting the stock's downward trajectory.
• Ongoing legal proceedings involving Eli Lilly and Johnson & Johnson regarding alleged health risks associated with their products may have raised investor apprehensions, contributing to the bearish market sentiment.
• Concerns regarding the lawsuit's potential repercussions on Eli Lilly's financial performance and image could be prompting investors to offload the stock.

01.04.2025 - LLY Stock was down 10.2%

• In spite of the strong upward momentum witnessed over the previous month and year, Eli Lilly (LLY) encountered a downward movement in its stock price today.
• This shift can be linked to the company falling short of Q1 earnings expectations, with a -5.11% surprise in earnings and a 0.86% miss in revenue.
• Moreover, the reduction in projected 2025 profit due to IPR&D-related expenses may have influenced investor sentiment, contributing to today's decline in the stock price.
• Investors are advised to keep a close watch on upcoming earnings releases and updates regarding the company's profitability forecast to assess the potential recovery of the stock from the current bearish trend.